



Press release |

IBA continues to reinforce its leadership in Proton Therapy

Louvain-la-Neuve, Belgium, January 19, 2011

Yesterday, during a visit of the proton therapy center in construction in Essen Germany with the press, Pierre Mottet, CEO of IBA, declared that the financing of the **project ordered by par Seattle Procure Management LLC** for the installation of a proton therapy system in Seattle, WA (USA) will be closed on Thursday January 20, which will allow to book this project as a firm order into the IBA backlog.

At the same occasion, he took the opportunity to announce that the claims filed by two competitors against the **Skandion Clinic project**, the clinical centre for proton therapy in Sweden has been definitively rejected by the Swedish authorities. The contract negotiations have therefore started again without limitations and should be finalized soon.

IBA is committed to making proton therapy, the most accurate cancer treatment, available worldwide. To date, IBA has been selected to install 24 proton therapy centers of which 11 are treating patients and 8 are under construction. This represents altogether more than half of the clinical-based proton therapy facilities in the world.

Proton therapy is increasingly considered the best radiotherapy for cancer due to its superior dose distribution. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor and, even better, spare healthy surrounding tissues. Higher doses can be delivered to the tumor without increasing the risk of side effects and long term complications, thereby improving outcome and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.

ABOUT IBA

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization. *Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).* Website: www.iba-worldwide.com

Contact

IBA

Jean-Marc Bothy

Chief Financial Officer

Phone: +32 10 47 58 90

Email : InvestorRelations@iba-group.com

IBA

Sandrine Leriche

VP Corporate Communication

Phone: +32 10 47 58 90

Email : Sandrine.leriche@iba-group.com